MaxCyte, Inc. (MXCT) News

MaxCyte, Inc. (MXCT): $4.41

0.07 (-1.56%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Filter MXCT News Items

MXCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MXCT News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest MXCT News From Around the Web

Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.

MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price

Key Insights MaxCyte's estimated fair value is UK£5.59 based on 2 Stage Free Cash Flow to Equity MaxCyte's UK£3.24...

Yahoo | January 1, 2025

MaxCyte Announces Retirement of Board Member Art Mandell

ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Art Mandell has retired from his position as a member of the Board of Directors of MaxCyte effective December 31, 2024. Mr. Mandell has served on the Board since 2006 and has been an integral part of MaxC

Yahoo | December 23, 2024

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This “bottom-up” review focused on optimizing ne

Yahoo | December 9, 2024

This MaxCyte Insider Increased Their Holding In The Last Year

Looking at MaxCyte, Inc.'s ( LON:MXCT ) insider transactions over the last year, we can see that insiders were net...

Yahoo | November 21, 2024

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

Since 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projectsROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, marks the 25th anniversary of its founding this year. Over the past quarter-century, the company has rem

Yahoo | November 13, 2024

MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...

MaxCyte Inc (MXCT) reports a 23% increase in core revenue and maintains a robust cash position, despite a decline in gross margin and drug discovery revenue.

Yahoo | November 7, 2024

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of 15.38% and 8.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 6, 2024

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its financial results for the third quarter ended September 30, 2024, and updated its 2024 guidance. Third Quarter and Recent Highlights Total revenue of $8.2 million in the third quarter of 2024, an increase

Yahoo | November 6, 2024

MaxCyte to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFires

Yahoo | October 31, 2024

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company

Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...

Yahoo | October 30, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!